Vanda Pharmaceuticals Inc (VNDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $230.39M
Last updated: Nov 17, 2026 at 4:33 PM ET
Vanda Pharmaceuticals Inc (VNDA) Statistics
Vanda Pharmaceuticals (VNDA) has a market cap of $230.39M and an enterprise value of $170.80M. It kept -119.87% of revenue as net income over the last 12 months. It holds $59.59M more cash than debt, 25.86% of its market cap.
Total Valuation
Enterprise value is 25.86% below the market cap, as cash exceeds debt.
| Market Cap | $230.39M |
|---|---|
| Enterprise Value | $170.80M |
| Latest price (Nov 17, 2026) | $3.81 |
Key Dates
The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.0x and 1.2x. Its year-end P/S ranged from 1.3x to 7.0x from 2016 to 2025.
| P/S Ratio | 1.0x |
|---|---|
| Forward P/S | 1.0x |
| P/B Ratio | 1.2x |
| P/TBV Ratio | 2.6x |
Price Statistics
The stock is down 12.41% over 52 weeks and trades 14.00% below its 50-day average.
| Beta (1Y) | 1.05 |
|---|---|
| 52-Week Change | -12.41% |
| 1-Month Change | -6.85% |
| 3-Month Change | -31.60% |
| 6-Month Change | -36.39% |
| 5-Year Change | -77.86% |
| 10-Year Change | -74.48% |
| Total Return (1Y) | -12.41% |
| Total Return (3Y CAGR) | +2.38% |
| Total Return (5Y CAGR) | -26.07% |
| Return vs SPY (1Y) | -40.34% |
| Max Drawdown (1Y) | -62.45% |
| Max Drawdown (3Y) | -62.45% |
| Sharpe Ratio (1Y) | -0.46 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $4.43 |
| 200-Day Average | $5.98 |
| 52-Week Range | $3.57 to $9.94 |
| RSI (14 Days) | 40.6 |
| Average Volume (20 Days) | 1.31M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.54x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 1.54x |
|---|---|
| Quick Ratio | 1.53x |
| Debt / Equity | 0.01x |
Returns and Efficiency
Return on invested capital is -84.67% over the last 12 months, against a 5-year average of -41.85%.
| Return on Equity (ROE) | -137.51% |
|---|---|
| Return on Assets (ROA) | -71.88% |
| Return on Invested Capital (ROIC) | -84.67% |
| Return on Capital Employed (ROCE) | -75.30% |
| ROE (5Y Average) | -12.54% |
| ROA (5Y Average) | -8.20% |
| ROIC (5Y Average) | -41.85% |
| Asset Turnover | 0.47x |
| Inventory Turnover | 9.17x |
| Receivables Turnover | 3.82x |
| Cash Conversion Cycle | -1485 days |
Scores
VNDA has an Altman Z-Score of -1.79, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.79 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $229.28M over the last 12 months is up 8.11% from the 12 months before.
| Revenue | $229.28M |
|---|---|
| Revenue Growth (YoY) | +8.11% |
| Gross Profit | $214.57M |
| Operating Income | -$177.91M |
| Pretax Income | -$171.20M |
| Net Income | -$274.83M |
| EBITDA | -$155.00M |
| EBIT | -$171.20M |
| Reported EPS (TTM) | -$4.62 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 52.27% of the $382.33M in total assets.
| Cash and Equivalents | $61.93M |
|---|---|
| Total Debt | $2.35M |
| Net Cash | $59.59M |
| Net Cash Per Share | $0.99 |
| Working Capital | $83.49M |
| Shareholder Equity | $199.86M |
| Book Value Per Share | $3.31 |
| Tangible Book Value | $88.73M |
| Tangible Book Per Share | $1.47 |
| Total Assets | $382.33M |
| Total Liabilities | $182.47M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $824.00K of capital spending, operating cash flow left -$139.96M of free cash flow.
| Operating Cash Flow | -$139.14M |
|---|---|
| Capital Expenditures | $824.00K |
| Free Cash Flow | -$139.96M |
| FCF Per Share | -$2.31 |
| Depreciation and Amortization | $16.19M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -77.59%, against a 5-year average of -15.89%.
| Gross Margin | 93.59% |
|---|---|
| Operating Margin | -77.59% |
| Pretax Margin | -74.67% |
| Net Margin | -119.87% |
| EBITDA Margin | -67.61% |
| EBIT Margin | -74.67% |
| FCF Margin | -61.05% |
| Gross Margin (5Y Average) | 92.30% |
| Operating Margin (5Y Average) | -15.89% |
| Net Margin (5Y Average) | -19.08% |
Growth
Revenue fell 5.29% a year over 3 years.
| Revenue Growth (3Y CAGR) | -5.29% |
|---|---|
| Revenue Growth (5Y CAGR) | -2.73% |
| Book Value Per Share Growth (2Y CAGR) | -23.55% |
| Tangible Book Per Share Growth (2Y CAGR) | -30.51% |
Dividends and Yields
VNDA does not pay a dividend. Its free cash flow yield is -60.76%.
| FCF Yield | -60.76% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 6 similar companies, VNDA has the lowest P/S.
P/S RatioPeer median 11.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -97.79%
| P/S Ratio | 1.0x vs 11.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.11% vs -97.79% median |
Analyst Forecast
Consensus estimates put revenue growth at 20.97% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +20.97% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VNDA
What is VNDA's market cap?
Vanda Pharmaceuticals has a market cap of $230.39M. Its enterprise value, which adds debt and subtracts cash, is $170.80M.
How many shares of VNDA are outstanding?
Vanda Pharmaceuticals has 60.47M shares outstanding. The count is up 2.32% from a year earlier.
Does VNDA pay a dividend?
No. Vanda Pharmaceuticals does not pay a dividend.
How much debt does VNDA have?
Vanda Pharmaceuticals has $2.35M of total debt and $61.93M of cash and equivalents, a net cash position of $59.59M.
VNDA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts